Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Kymab, Morphosys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Jul 6, 2016
Initiation of Phase 1 Clinical Study with Novel Immuno-Oncology Candidate Triggers US$10 Million Milestone Payment from AstraZeneca
Jun 29, 2016
Heptares and leadXpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery
Events

Oct 27-28, 2016
Peptide Therapeutics Symposium
La Jolla, CA, USA
Presenting: Ali Jazayeri

Oct 30 - Nov 4, 2016
PEGS Europe Protein & Antibody Engineering Summit
Lisbon, Portugal
Presenting: Catherine Hutchings

© 2012-2016 Heptares Therapeutics